valproic acid has been researched along with Adenocarcinoma, Basal Cell in 15 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid has been demonstrated to mediate cytotoxic effects against tumor cells by acting as a histone-deacetylase inhibitor." | 5.33 | Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. ( Atmaca, A; Chow, KU; Friedmann, I; Jäger, E; Weidmann, E, 2006) |
| "The development of immunotherapy for pancreatic cancer has been hampered by difficulty in generating tumor-reactive lymphocytes from resected specimens and by a lack of appropriate target antigens expressed on tumor cells." | 1.38 | Targeting the MAGE A3 antigen in pancreatic cancer. ( Cogdill, AP; Cooper, ZA; Ferrone, CR; Fiedler, A; Frederick, DT; Garber, HR; Rosenberg, L; Thayer, SP; Wargo, JA; Warshaw, AL, 2012) |
| "Valproic acid (VPA) is a promising anticancer agent recently assigned to the class of histone deacetylase (HDAC) inhibitors." | 1.35 | Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma. ( Angelucci, A; Bologna, M; Cerù, MP; Cimini, A; Cristiano, L; Dolo, V; Miano, R; Millimaggi, D; Muzi, P; Vicentini, C, 2008) |
| "Valproic acid has been demonstrated to mediate cytotoxic effects against tumor cells by acting as a histone-deacetylase inhibitor." | 1.33 | Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. ( Atmaca, A; Chow, KU; Friedmann, I; Jäger, E; Weidmann, E, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Perrino, E | 1 |
| Cappelletti, G | 1 |
| Tazzari, V | 1 |
| Giavini, E | 1 |
| Del Soldato, P | 1 |
| Sparatore, A | 1 |
| Petry, SF | 1 |
| Kandula, ND | 1 |
| Günther, S | 1 |
| Helker, C | 1 |
| Schagdarsurengin, U | 1 |
| Linn, T | 1 |
| Anirudh, BVM | 1 |
| Ezhilarasan, D | 1 |
| Nagai, H | 1 |
| Fujioka-Kobayashi, M | 1 |
| Ohe, G | 1 |
| Hara, K | 1 |
| Takamaru, N | 1 |
| Uchida, D | 1 |
| Tamatani, T | 1 |
| Fujisawa, K | 1 |
| Miyamoto, Y | 1 |
| Ding, S | 1 |
| Pickard, AJ | 1 |
| Kucera, GL | 1 |
| Bierbach, U | 1 |
| Sun, R | 1 |
| Zhang, S | 1 |
| Hu, W | 1 |
| Lu, X | 1 |
| Lou, N | 1 |
| Yang, Z | 2 |
| Chen, S | 1 |
| Zhang, X | 1 |
| Yang, H | 1 |
| Wedel, S | 2 |
| Hudak, L | 2 |
| Seibel, JM | 2 |
| Juengel, E | 2 |
| Oppermann, E | 1 |
| Haferkamp, A | 2 |
| Blaheta, RA | 2 |
| Tsaur, I | 1 |
| Wiesner, C | 1 |
| Cogdill, AP | 1 |
| Frederick, DT | 1 |
| Cooper, ZA | 1 |
| Garber, HR | 1 |
| Ferrone, CR | 1 |
| Fiedler, A | 1 |
| Rosenberg, L | 1 |
| Thayer, SP | 1 |
| Warshaw, AL | 1 |
| Wargo, JA | 1 |
| Graziani, G | 1 |
| Tentori, L | 1 |
| Portarena, I | 1 |
| Vergati, M | 1 |
| Navarra, P | 1 |
| Gibbs, JP | 1 |
| Adeyeye, MC | 1 |
| Shen, DD | 1 |
| Dmytriyev, A | 1 |
| Tkach, V | 1 |
| Rudenko, O | 1 |
| Bock, E | 1 |
| Berezin, V | 1 |
| Friedmann, I | 1 |
| Atmaca, A | 1 |
| Chow, KU | 1 |
| Jäger, E | 1 |
| Weidmann, E | 1 |
| Angelucci, A | 1 |
| Muzi, P | 1 |
| Cristiano, L | 1 |
| Millimaggi, D | 1 |
| Cimini, A | 1 |
| Dolo, V | 1 |
| Miano, R | 1 |
| Vicentini, C | 1 |
| Cerù, MP | 1 |
| Bologna, M | 1 |
| Watkins, JR | 1 |
| Gough, AW | 1 |
| McGuire, EJ | 1 |
| Goldenthal, E | 1 |
| de la Iglesia, FA | 1 |
15 other studies available for valproic acid and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity.
Topics: Acetylation; Adenocarcinoma; Apoptosis; Blotting, Western; Cell Proliferation; Enzyme Inhibitors; Hi | 2008 |
Valproic Acid Initiates Transdifferentiation of the Human Ductal Adenocarcinoma Cell-line Panc-1 Into α-Like Cells.
Topics: Adenocarcinoma; Cell Transdifferentiation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Hist | 2022 |
Reactive Oxygen Species-Mediated Mitochondrial Dysfunction Triggers Sodium Valproate-Induced Cytotoxicity in Human Colorectal Adenocarcinoma Cells.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Mitoch | 2021 |
Antitumour effect of valproic acid against salivary gland cancer in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Ki | 2014 |
Design of enzymatically cleavable prodrugs of a potent platinum-containing anticancer agent.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Humans | 2014 |
Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Topics: Adenocarcinoma; Animals; Binding Sites; Cachexia; Carcinoma, Lewis Lung; CCAAT-Enhancer-Binding Prot | 2016 |
Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.
Topics: Adenocarcinoma; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Screening Assays, A | 2011 |
Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Move | 2011 |
Targeting the MAGE A3 antigen in pancreatic cancer.
Topics: Adenocarcinoma; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Chromatin Assembly and Disassembl | 2012 |
Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells.
Topics: Adenocarcinoma; Cell Division; Drug Synergism; Endometrial Neoplasms; Enzyme Inhibitors; Estradiol; | 2003 |
Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport.
Topics: Adenocarcinoma; Animals; Biological Transport, Active; Brain; Cattle; Cells, Cultured; Cyclooxygenas | 2004 |
An automatic procedure for evaluation of single cell motility.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Movement; Enzyme Inhibitors; Fibroblasts; Glioma; Gr | 2006 |
Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; | 2006 |
Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma.
Topics: Adenocarcinoma; Anilides; Animals; Cell Line, Tumor; Cell Proliferation; Cell Transdifferentiation; | 2008 |
Calcium valproate-induced uterine adenocarcinomas in Wistar rats.
Topics: Adenocarcinoma; Administration, Oral; Animals; Body Weight; Female; Kidney Neoplasms; Male; Rats; Ra | 1992 |